[go: up one dir, main page]

PE20151669A1 - Compuestos de azetidiniloxifenilpirrolidina - Google Patents

Compuestos de azetidiniloxifenilpirrolidina

Info

Publication number
PE20151669A1
PE20151669A1 PE2015001904A PE2015001904A PE20151669A1 PE 20151669 A1 PE20151669 A1 PE 20151669A1 PE 2015001904 A PE2015001904 A PE 2015001904A PE 2015001904 A PE2015001904 A PE 2015001904A PE 20151669 A1 PE20151669 A1 PE 20151669A1
Authority
PE
Peru
Prior art keywords
compounds
azetidinyloxphenylpyrrolidine
refers
pde4
methyl
Prior art date
Application number
PE2015001904A
Other languages
English (en)
Inventor
Gary G Deng
Danwen Huang
Joshua O Odingo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20151669A1 publication Critical patent/PE20151669A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE AZETIDINILOXIFENILPIRROLIDINA DE FORMULA I COMO INHIBIDORES DE PDE4, EN DONDE R ES HIDROGENO O METILO. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS COMPUESTOS. LOS COMPUESTOS DE LA PRESENTE INVENCION SON UTILES EN EL TRATAMIENTO DE LA VEJIGA SOBRERREACTIVA Y OTROS TRASTORNOS ASOCIADOS CON PDE4
PE2015001904A 2013-03-13 2014-03-07 Compuestos de azetidiniloxifenilpirrolidina PE20151669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
PE20151669A1 true PE20151669A1 (es) 2015-11-12

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001904A PE20151669A1 (es) 2013-03-13 2014-03-07 Compuestos de azetidiniloxifenilpirrolidina

Country Status (39)

Country Link
US (3) US9034864B2 (es)
EP (2) EP3168216A1 (es)
JP (2) JP6017708B2 (es)
KR (2) KR101702797B1 (es)
CN (2) CN109336865A (es)
AP (1) AP3850A (es)
AR (1) AR095015A1 (es)
AU (1) AU2014241444B2 (es)
BR (1) BR112015020222B1 (es)
CA (1) CA2899806C (es)
CL (1) CL2015002113A1 (es)
CR (1) CR20150417A (es)
CY (1) CY1120142T1 (es)
DK (1) DK2970222T3 (es)
DO (1) DOP2015000176A (es)
EA (1) EA026631B1 (es)
ES (1) ES2616470T3 (es)
HR (1) HRP20170080T1 (es)
HU (1) HUE032235T2 (es)
IL (1) IL240904B (es)
JO (1) JO3264B1 (es)
LT (1) LT2970222T (es)
MA (1) MA38410B1 (es)
ME (1) ME02592B (es)
MX (1) MX373636B (es)
MY (1) MY180006A (es)
NZ (1) NZ710481A (es)
PE (1) PE20151669A1 (es)
PH (1) PH12015502032A1 (es)
PL (1) PL2970222T3 (es)
PT (1) PT2970222T (es)
RS (1) RS55594B1 (es)
SG (2) SG11201507501YA (es)
SI (1) SI2970222T1 (es)
TN (1) TN2015000384A1 (es)
TW (1) TWI617553B (es)
UA (1) UA115583C2 (es)
WO (1) WO2014159012A1 (es)
ZA (1) ZA201505417B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
AR101696A1 (es) * 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
AU2019408336B2 (en) * 2018-12-18 2022-03-10 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Phenylpyrrolidine compound and use thereof
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN112409333B (zh) * 2019-08-23 2024-06-14 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2436551A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
WO2007039075A2 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Also Published As

Publication number Publication date
JP2016510759A (ja) 2016-04-11
AU2014241444A1 (en) 2015-08-06
JO3264B1 (ar) 2018-09-16
IL240904B (en) 2019-02-28
PL2970222T3 (pl) 2017-06-30
US20160122322A1 (en) 2016-05-05
EP3168216A1 (en) 2017-05-17
DOP2015000176A (es) 2015-11-15
BR112015020222A8 (pt) 2018-01-23
IL240904A0 (en) 2015-10-29
LT2970222T (lt) 2017-03-27
EP2970222B1 (en) 2016-12-21
SI2970222T1 (sl) 2017-02-28
PT2970222T (pt) 2017-02-08
NZ710481A (en) 2020-08-28
AU2014241444B2 (en) 2016-04-07
MX2015012579A (es) 2016-01-20
CA2899806C (en) 2017-07-18
CN105051034A (zh) 2015-11-11
MA38410B1 (fr) 2016-09-30
TWI617553B (zh) 2018-03-11
HRP20170080T1 (hr) 2017-03-10
ES2616470T3 (es) 2017-06-13
CR20150417A (es) 2015-09-16
WO2014159012A9 (en) 2014-12-18
ZA201505417B (en) 2022-09-28
EA026631B1 (ru) 2017-04-28
US20140275002A1 (en) 2014-09-18
TW201522327A (zh) 2015-06-16
HK1212695A1 (en) 2016-06-17
CL2015002113A1 (es) 2016-01-15
US9034864B2 (en) 2015-05-19
CY1120142T1 (el) 2018-12-12
KR20150119077A (ko) 2015-10-23
ME02592B (me) 2017-06-20
CN105051034B (zh) 2019-05-21
PH12015502032A1 (en) 2016-01-18
EA201591498A1 (ru) 2015-12-30
JP2016216517A (ja) 2016-12-22
KR20170013411A (ko) 2017-02-06
US9604967B2 (en) 2017-03-28
WO2014159012A1 (en) 2014-10-02
DK2970222T3 (en) 2017-02-27
BR112015020222A2 (pt) 2017-07-18
AP2015008699A0 (en) 2015-09-30
US20150133423A1 (en) 2015-05-14
JP6204557B2 (ja) 2017-09-27
BR112015020222B1 (pt) 2020-07-14
AP3850A (en) 2016-09-30
HUE032235T2 (en) 2017-09-28
AR095015A1 (es) 2015-09-16
EP2970222A1 (en) 2016-01-20
JP6017708B2 (ja) 2016-11-02
MY180006A (en) 2020-11-19
SG10201609717YA (en) 2017-01-27
MX373636B (es) 2020-04-16
SG11201507501YA (en) 2015-10-29
US9266859B2 (en) 2016-02-23
CN109336865A (zh) 2019-02-15
RS55594B1 (sr) 2017-06-30
CA2899806A1 (en) 2014-10-02
KR101702797B1 (ko) 2017-02-06
KR101745304B1 (ko) 2017-06-08
UA115583C2 (uk) 2017-11-27
TN2015000384A1 (en) 2017-01-03
MA38410A1 (fr) 2016-02-29

Similar Documents

Publication Publication Date Title
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150571A (es) Compuestos y composiciones terapéuticos
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CR20150250A (es) Nuevos derivados de piridina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CR20150447A (es) Nuevos derivados de pirazol
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
MX2017001279A (es) Usos y composiciones de la flagelina.
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
ECSP13013074A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20150440A (es) Nuevos derivados de piridina
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX2017007377A (es) Compuestos organicos.
CR20150511A (es) Nuevos derivados de purina
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos

Legal Events

Date Code Title Description
FG Grant, registration